Skip to main content
Erschienen in: Journal of Translational Medicine 1/2019

Open Access 01.12.2019 | Research

miRNA deregulation targets specific pathways in leiomyosarcoma development: an in silico analysis

verfasst von: Clara Benna, Senthilkumar Rajendran, Marco Rastrelli, Simone Mocellin

Erschienen in: Journal of Translational Medicine | Ausgabe 1/2019

Abstract

Background

MicroRNA (miRNA) mediate post-transcriptional gene repression and are involved in a variety of human diseases, including cancer. Soft tissue sarcomas are rare malignancies with a variety of histological subtypes which may occur virtually anywhere in the human body. Leiomyosarcoma is one of the most common subtypes, shows a smooth muscle phenotype and its cancerogenesis is still unclear. The aim of our study was to investigate the potential role of miRNA differential expression in leiomyosarcoma development.

Methods

We first employed the Sarcoma microRNA Expression Database, a repository that describes the patterns of over 1000 miRNA expression in various human sarcoma types, to identify differentially expressed miRNA comparing leiomyosarcoma and smooth muscle samples. Subsequently, we identified putative target genes of those miRNAs with the TargetScan prediction tool. Finally, we evaluated whether the retrieved pool of putative targets was enriched in genes belonging to specific molecular pathways by means of the Enrichr analysis tool. Protein–protein network analysis was analyzed by means of the STRING web tool.

Results

Out of 1120 miRNAs tested, the expression of 301 miRNAs was statistically significantly different between leiomyosarcoma and smooth muscle samples. The hypothetical targets could be predicted for 172 miRNAs. 438 genes were predicted to be the targets with high confidence (cumulative weighted context score cut-off level less than − 1.0) and analyzed for belonging to specific molecular pathways. Pathway analysis suggested that RNA Polymerase III, tRNA functions and synaptic neurotransmission (with special regard to dopamine mediated signaling) could be involved in leiomyosarcoma development.

Conclusions

Our results demonstrate that data mining of publicly available repositories can be useful to suggest molecular pathways underlying the pathogenesis of rare tumors such as leiomyosarcoma.
Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12967-019-1907-2) contains supplementary material, which is available to authorized users.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
miRNA
microRNA
STS
soft tissue sarcoma
S-MED
Sarcoma microRNA Expression Database
CS
context++ score
GSEA
gene set enrichment analysis
FDR
false discovery rate
pol III
RNA polymerase III
pol I
RNA polymerase I
TFIII
pol III transcription factor
DRs
dopamine receptors
DR1
D1-like receptor family
DR2
D2-like receptor family

Background

Leiomyosarcoma is the second most frequent type of soft tissue sarcoma (STS) accounting for approximately 14% of all cases and is defined as demonstrating a smooth muscle phenotype with immunohistochemistry [1, 2]. This rare tumor may occur virtually anywhere in the human body, from the limbs and trunk to the viscera and the retroperitoneum. Surgery remains the mainstay of treatment of localized leiomyosarcoma, but disease recurrence occurs frequently and chemotherapy is poorly effective to control metastatic disease [3]. Therefore, new therapies are eagerly needed in order to improve the prognosis of these patients. To this aim, understanding the cascade of molecular events leading to the development and progression of leiomyosarcoma plays a pivotal role in the identification of therapeutic targets.
miRNAs are 22–25 nucleotide RNAs that mediate post-transcriptional gene repression [4]. They are involved in a variety of human diseases, including malignancies, such as endometrial cancer [5], colorectal cancer [6], testicular cancer [7], acute myeloid leukemia [8], lung carcinoma [9], lymphoma [10], breast cancer [11] and osteosarcoma [12]. They can exert oncogenic functions as overexpressed miRNAs or serve as tumor suppressors and are consequently downregulated in the respective malignancy [1315].
In this regard, recently, leiomyosarcoma has also been studied, moreover Authors’ attention has focused on miRNA signatures for their emerging potential as diagnostic biomarkers and for aiding subclassification [1618], nevertheless the knowledge on this field of research is still poor.
The aim of our study is to further dissect molecular pathways involved in leiomyosarcoma development and progression. In a previous analysis [19] we explored the possible relation between the circadian clock pathway and soft tissue sarcoma (with special regard to leiomyosarcoma) susceptibility in terms of genetic variability. Here, we adopted a different strategy. First, we employed Sarcoma microRNA Expression Database (S-MED) https://​www.​oncomir.​umn.​edu/​SMED/​basic_​search.​php, a repository that describes the patterns of over 1000 miRNAs expression in various human sarcoma types, to individuate differentially expressed miRNA comparing leiomyosarcoma and smooth muscle tissues [20]. Subsequently, we identified putative target genes of those miRNAs with TargetScan prediction tool http://​www.​targetscan.​org/​ [21]. Finally, we evaluated whether the retrieved pool of putative targets was enriched in genes belonging to specific pathways http://​amp.​pharm.​mssm.​edu/​Enrichr/​ [22]. Finally, further insights in the interactions across gene products were evaluated by means of network analysis using the STRING web tool.

Methods

Study design

The objective of this study is to identify gene pathways whose expression is preferentially altered in leiomyosarcoma development. To achieve this goal we proceeded with the following 3 steps:
1.
miRNAs finding: identification of differentially expressed miRNAs in leiomyosarcoma and smooth muscle tissues.
 
2.
miRNAs to genes: identification of differentially expressed miRNAs target genes.
 
3.
From genes to pathways: identification of gene pathways of differentially expressed miRNAs targets.
 

1. miRNAs finding

Sarcoma-microRNA Expression Database (S-MED) [20] was employed to retrieve miRNA expression data in leiomyosarcoma and in smooth muscle. S-MED is a repository that describes the patterns of miRNA expression found in various human sarcoma tumor types and select normal tissues. S-MED provides both Basic and Advanced data search options for exploration of the data by means of heat-maps and text formats. Raw data were extracted for each of the considered miRNA. miRNAs in which the expression was not available in both leiomyosarcoma and smooth muscle were excluded. For each miRNA Student’s T-test was performed to assess significantly differentially expressed miRNAs between leiomyosarcoma and smooth muscle tissues. Bonferroni correction for multiple testing was applied to define the level of significance. P-values smaller than 4.50E−05 were considered significant.

2. miRNAs to genes

TargetScan (v7.0; targetscan.org) [21] on line tool was employed for predicting effective microRNA target sites in human mRNAs. TargetScan predicts biological targets of miRNAs by searching for the presence of conserved 8mer, 7mer, and 6mer sites that match the seed region of each miRNA [23]. In mammals, predictions are ranked based on the predicted efficacy of targeting as calculated using cumulative weighted context++ scores of the sites [21]. The context++ score (CS) for a specific site is the sum of the contribution of 14 features [21]: site type, supplementary pairing, local AU, minimum distance, sRNA1A, sRNA1C, sRNA1G, sRNA8A, sRNA8C, sRNA8G, site8A, site8C, site8G, 3′ UTR length, SA, ORF length, ORF 8mer count, 3′ UTR offset 6mer count, TA (target site abundance), SPS (seed-pairing stability), PCT (probability of conserved targeting). The cumulative weighted CS cut-off was set up at − 1.0 in order to minimize false positive associations between miRNA and their targets, as well as to yield a manageable number of targets to be considered with both enrichment and network analysis [24].

3. From genes to pathways

Once target genes were identified, we used them to perform pathway analysis in order to identify biological functions whose genetic perturbations can predispose to leiomyosarcoma development.
For pathway analysis purposes, we utilized gene set enrichment analysis (GSEA) as performed by the EnrichR web server [22]. Hypergeometric distribution was used to calculate the statistical significance of gene overlapping [25], followed by correction for multiple hypotheses testing (using the false discovery rate [FDR] method) [26]. Only pathways with a FDR < 0.05 were considered of interest.
In contrast to pathways, networks are not based on specific biological functions but are built based on both direct (physical) and indirect (genetic) interactions between gene products (proteins). For network analysis, we utilized the STRING 11.0 web server [27]. The resulting network provides information of the degree of overall connectivity across imputed gene products (as quantified by the ratio between observed and expected interactions [a.k.a. “edges”] between proteins [a.k.a. “nodes”], and formally tested by means of a PPI enrichment test). Moreover, it suggests cluster of interacting proteins, which can help identify specific cell pathways.

Results

Differentially expressed miRNAs

The results are summarized in the flow chart in Fig. 1. In the first step of this study, we compared the expression between leiomyosarcoma and smooth muscle tissues of 1120 miRNAs whose expression data were stored in Sarcoma-microRNA Expression Database (S-MED). For each miRNA data were available for 32 samples (22 leiomyosarcoma tissues and 10 smooth muscle tissues). The expression of 301 miRNAs was statistically significantly different (P-value < 4.5 E−05) between neoplastic and normal tissues (see Additional file 1: Table S1). The hypothetical targets could be predicted for 172 miRNAs by the target prediction tool TargetScan. For 129 miRNAs, mostly star miRNAs (the complementary strand of the unstarred), target prediction was not possible: for this reason, those miRNAs were excluded from further analysis. Employing a cumulative weighted context score cut-off level of − 1.0 the retrieved putative gene targets were 608 (see Additional file 2: Table S2). After removing duplicates (which is because two or more miRNAs can share one or more target genes), the predicted targets resulted 438, which were considered for pathway analysis (see below section).

From genes to pathways

Primary gene set enrichment analysis suggested that the 438 putative miRNA targets are enriched in genes involved in RNA polymerase III and tRNA functions (as transcription initiation, elongation, termination and tRNA modification) and in synaptic neurotransmission. Interrogating the KEGG and Reactome databases, the EnrichR webtool returned the results reported in Table 1. Network analysis of proteins encoded by miRNA targets showed that the overall connectivity was significantly greater than expected (144/122 edges, P = 0.03) and confirmed the results obtained by enrichment analysis, especially underscoring the high number of interactions between proteins involved in neurotransmission (see Fig. 2).
Table 1
Pathway analysis main findings: gene set enrichment analysis based on 438 miRNA target genes
Pathway
Overlap
FDR
Genes
Database
RNA polymerase III functions
 RNA polymerase III transcription termination
4/23
0.0014
NFIC; POLR3G; POLR3H; POLR2K
REACTOME
 RNA polymerase III chain elongation
3/18
0.0067
POLR3G; POLR3H; POLR2K
REACTOME
 tRNA modification in the nucleus and cytosol
4/39
0.0102
URM1; ADAT1; LCMT2; OSGEP
REACTOME
 RNA polymerase III transcription
4/41
0.0121
NFIC; POLR3G; POLR3H; POLR2K
REACTOME
 RNA polymerase III
3/32
0.0324
POLR3G; POLR3H; POLR2K
KEGG
Synaptic neurotransmission
 Dopaminergic synapse
9/129
0.0022
KCNJ6; ATF6B; KCNJ9; PPP2R2D; CACNA1A; GRIN2B; CREB5; GNG13; MAPK13
KEGG
 Synapse formation and maturation (LGI-ADAM interactions)
3/14
0.0032
CACNG8; ADAM22; CACNG2
REACTOME
 Depolarization of the presynaptic terminal triggers the opening of calcium channels
2/13
0.0318
CACNA1A; CACNG2
REACTOME
 Neurotransmitter receptor binding and downstream transmission in the postsynaptic cell
7/142
0.0370
CACNG8; KCNJ6; KCNJ9; GRIK3; CACNG2; GRIN2B; GNG13
REACTOME
 Morphine addiction
5/91
0.0496
KCNJ6; KCNJ9; CACNA1A; GABRG1; GNG13
KEGG
Other pathways
 Extrinsic pathway of fibrin clot formation
2/5
0.0046
F7; TFPI
REACTOME
 Chemokine receptors bind chemokines
5/56
0.0075
CCL22; CCL7; ACKR2; CXCL2; CXCL16
REACTOME
 TP53 regulates transcription of genes involved in G1 cell cycle arrest
2/13
0.0318
CCNE1; ZNF385A
REACTOME
 Regulation of TP53 activity through association with co-factors
2/14
0.0366
ZNF385A; TP73
REACTOME
 Hematopoietic cell lineage
5/88
0.0440
FCER2; CSF2; TFRC; ITGA1; CD3E
KEGG
 Protein digestion and absorption
5/90
0.0477
COL1A1; SLC6A19; COL3A1; COL12A1; SLC8A2
KEGG
FDR false discovery rate

Discussion

The aim of our study was to identify molecular pathways whose expression is particularly affected during leiomyosarcoma development. Our approach was first to identify miRNA which are statistically significantly down or up-regulated in leiomyosarcoma compared to smooth muscle, second to predict putative targets of those miRNA, and third to analyze if those putative target genes belonged to specific molecular pathways. Our results suggest that RNA Polymerase III, tRNA functions and synaptic neurotransmission could be altered during leiomyosarcoma development.

RNA polymerase III, tRNA and cancer

RNA polymerase III (pol III) is the largest RNA polymerase with the greatest number of subunits. It synthesizes a range of essential products, including tRNA, 5S rRNA and 7SL RNA, which are required for protein synthesis and trafficking. Moreover, while RNA polymerase I (pol I) synthesizes three ribosome subunits as a single precursor transcript that is processed into the final mature products, pol III produces MPR RNA, necessary for the processing; for a review see [28, 29]. Abnormal pol III activity has been proposed to be feature of cancer cells. rRNA and tRNA are overproduced consistently in different human cancers as ovarian [30] breast, lung and tongue carcinomas [31, 32]. Conversely, in healthy cells oncogenes and tumor suppressor signaling pathways, such as the PI3kinase/TORC1, Ras/ERK, Myc, p53 and Rb pathways, regulate Pol III and tRNA synthesis. In particular, pol III transcription factor (TFIIIB) interacts with the tumor suppressors RB and p53 to limit pol III production [33, 34]. Regarding tRNA, a pathway not related to pol III has also been identified in our study, which is tRNA modification in the nucleus and cytosol. Wobble tRNA modifications are required during translation elongation and sustain proteome homeostasis. A recent work has highlighted the upregulation of the wobble uridine 34 (U34) tRNA cascade in cancer, which underlies the specific requirement for this pathway in tumor development [35]. It is plausible to suppose that a further mechanism of controlling pol III abundance and tRNA production and maturation is due to miRNAs. Our results support this hypothesis and suggest that evading this form of control could contribute to leiomyosarcoma development.

Dopamine

Dopamine is a monoamine neurotransmitter, synthesized from the amino acid tyrosine, which is transported from the liver to the brain via an active transport mechanism. Dopamine plays central role in pleasurable reward behavior, hormone secretion, sleep, mood, attention, learning, behavior, control of nausea and vomiting, and pain processing.
Due to extensive localization of dopamine receptor to brain areas and its role in wide range of functions, dopaminergic dysfunction has been implicated in the pathophysiology of mood disorders, schizophrenia, obsessive compulsive disorder, autism spectrum disorders, attention deficit–hyperactivity disorder, Tourette’s syndrome, substance dependency, Parkinson’s disease and other disorders [36, 37].
Dopamine receptors (DRs) belong to the family of seven transmembrane domain G-protein coupled receptors and are classified into D1-like (DR1) and D2-like receptor families (DR2) based on pharmacological properties, structure, and signal transduction system. DRs subtypes are expressed not only in brain areas, but also in many tissues and organs as kidney, heart, and the peripheral nervous. For this reason, this catecholamine also modulates cardiovascular function, vascular tone, renal function, and gastrointestinal motility.

Dopamine and smooth muscle

In recent works, many Authors found that the dopamine DR1 receptors are expressed on airway smooth muscle and regulate smooth muscle force via cAMP activation of PKA [38]. Moreover, it is reported that DR1 activation inhibited proliferation of the vascular smooth muscle cells [39].

Dopamine and osteosarcoma

Gao et al. [40] results suggest that DR1 are expressed in the osteosarcoma cells and inhibit the proliferation of osteosarcoma cells by the down-regulation of the ERK1/2 and PI3K-Akt pathways. In a different study, the same research group [41] suggested that activation of DR1 induces osteosarcoma cell apoptosis via changes to the MAPK pathway. The Authors proposed DR1 as a novel target for the treatment of osteosarcoma.
Here, the results of the present study support the hypothesis that dopamine pathway is involved in sarcoma growth and development and in particular in leiomyosarcoma.

Potassium voltage-gated channel and cancer

Considering each of the single target genes listed in this pathway, we found two potassium voltage-gated channel: Potassium Voltage-Gated Channel Subfamily J Member 6 (KCNJ6) and Potassium Voltage-Gated Channel Subfamily J Member 9 (KCNJ9). The ultimate effect of DR1 can be excitation (via opening of sodium channels) or inhibition (via opening of potassium channels). Voltage-gated potassium channels (Kv), encoded by 40 genes in humans, are the largest subset of potassium channels gated by changes in the membrane potential [42]. Numerous studies have reported dysregulated potassium channel expression in human cancer [43]. In particular, few Authors focused on sarcoma: a study showed that that Kv1.3 voltage-gated potassium channels was upregulated in human osteosarcoma and downregulation of Kv1.3 suppressed osteosarcoma growth in vivo and osteosarcoma cell proliferation in vitro, accompanied by increased apoptosis [44]. Similar results were shown for the voltage-gated potassium channels Ether à go-go 1 and Kv1.5 [45, 46].

Limitations

This study provides useful insights for further studies, nevertheless it is limited by a number of weaknesses. The initial analysis was carried out on 1120 miRNAs for which data were available on SMED: nevertheless, identified human miRNA are at least twice as much (as reported by international databases such as MirBase, http://​www.​mirbase.​org/​), which leaves room for many more miRNAs to be evaluated in leiomyosarcoma pathogenesis. In addition, we could retrieve hypothetical target genes only for a miRNA subset because the TargetScan repository does not report data on star miRNAs, which, although usually degraded, sometimes also function as gene expression regulators [47, 48]. Moreover, the analyses reported by the SMED web tool were based on 22 cases and 10 control samples: this small sample size does not protect against both false positive and false negative association results. As regards the target genes we have identified as potentially targeted by miRNA specifically deregulated in leiomyosarcoma, we could not validate our results in silico due to the lack of publicly available data on leiomyosarcoma. Consequently, dedicated experiments on human leiomyosarcoma samples are necessary to verify our hypothesis. Finally, though our results might suggest new therapeutic targets in the fight against leiomyosarcoma, experimental evidence proving the efficacy of this strategy is obviously warranted.

Conclusions

In soft tissue sarcomas, various miRNAs are differentially expressed, supporting the hypothesis that they could contribute to development, progression and invasion of this rare group of malignancies. Here, we focused on leiomyosarcoma, one of the most frequent types of soft tissue sarcomas. Overall our results suggest that there are pathways particularly targeted by miRNA altered expression which are already been linked to other malignancies, but are worth to be studied in leiomyosarcoma such as RNA pol III and tRNA functions and dopamine neurotransmission pathway. Expression and functional studies are needed to ascertain the role of these specific pathways in leiomyosarcoma development.
In general, our results demonstrate that data mining of publicly available repositories can be useful to suggest molecular pathways underlying the pathogenesis of rare tumors such as leiomyosarcoma.

Acknowledgements

Not applicable.
Not applicable.
Not applicable.

Competing interests

The authors declare that they have no conflict of interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Danielson LS, Menendez S, Attolini CS, Guijarro MV, Bisogna M, Wei J, et al. A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy. Am J Pathol. 2010;177(2):908–17.PubMedPubMedCentralCrossRef Danielson LS, Menendez S, Attolini CS, Guijarro MV, Bisogna M, Wei J, et al. A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy. Am J Pathol. 2010;177(2):908–17.PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Stiller CA, Botta L, Brewster DH, Ho VKY, Frezza AM, Whelan J, et al. Survival of adults with cancers of bone or soft tissue in Europe-report from the EUROCARE-5 study. Cancer Epidemiol. 2018;56:146–53.PubMedCrossRef Stiller CA, Botta L, Brewster DH, Ho VKY, Frezza AM, Whelan J, et al. Survival of adults with cancers of bone or soft tissue in Europe-report from the EUROCARE-5 study. Cancer Epidemiol. 2018;56:146–53.PubMedCrossRef
3.
Zurück zum Zitat Ducimetiere F, Lurkin A, Ranchere-Vince D, Decouvelaere AV, Peoc’h M, Istier L, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS ONE. 2011;6(8):e20294.PubMedPubMedCentralCrossRef Ducimetiere F, Lurkin A, Ranchere-Vince D, Decouvelaere AV, Peoc’h M, Istier L, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS ONE. 2011;6(8):e20294.PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Jurcevic S, Klinga-Levan K, Olsson B, Ejeskar K. Verification of microRNA expression in human endometrial adenocarcinoma. BMC Cancer. 2016;2(16):261.CrossRef Jurcevic S, Klinga-Levan K, Olsson B, Ejeskar K. Verification of microRNA expression in human endometrial adenocarcinoma. BMC Cancer. 2016;2(16):261.CrossRef
6.
Zurück zum Zitat Pichler M, Winter E, Ress AL, Bauernhofer T, Gerger A, Kiesslich T, et al. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. J Clin Pathol. 2014;67(3):198–203.PubMedCrossRef Pichler M, Winter E, Ress AL, Bauernhofer T, Gerger A, Kiesslich T, et al. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. J Clin Pathol. 2014;67(3):198–203.PubMedCrossRef
7.
Zurück zum Zitat Ling H, Krassnig L, Bullock MD, Pichler M. MicroRNAs in testicular cancer diagnosis and prognosis. Urol Clin North Am. 2016;43(1):127–34.PubMedCrossRef Ling H, Krassnig L, Bullock MD, Pichler M. MicroRNAs in testicular cancer diagnosis and prognosis. Urol Clin North Am. 2016;43(1):127–34.PubMedCrossRef
8.
Zurück zum Zitat Gong JN, Yu J, Lin HS, Zhang XH, Yin XL, Xiao Z, et al. The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia. Cell Death Differ. 2014;21(1):100–12.PubMedCrossRef Gong JN, Yu J, Lin HS, Zhang XH, Yin XL, Xiao Z, et al. The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia. Cell Death Differ. 2014;21(1):100–12.PubMedCrossRef
9.
Zurück zum Zitat Yin Z, Xu M, Li P. miRNA-221 acts as an oncogenic role by directly targeting TIMP2 in non-small-cell lung carcinoma. Gene. 2017;15(620):46–53.CrossRef Yin Z, Xu M, Li P. miRNA-221 acts as an oncogenic role by directly targeting TIMP2 in non-small-cell lung carcinoma. Gene. 2017;15(620):46–53.CrossRef
10.
Zurück zum Zitat Troppan K, Wenzl K, Deutsch A, Ling H, Neumeister P, Pichler M. MicroRNAs in diffuse large B-cell lymphoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res. 2014;34(2):557–64.PubMed Troppan K, Wenzl K, Deutsch A, Ling H, Neumeister P, Pichler M. MicroRNAs in diffuse large B-cell lymphoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res. 2014;34(2):557–64.PubMed
11.
Zurück zum Zitat Bertoli G, Cava C, Castiglioni I. The potential of miRNAs for diagnosis, treatment and monitoring of breast cancer. Scand J Clin Lab Invest Suppl. 2016;245:S34–9.PubMedCrossRef Bertoli G, Cava C, Castiglioni I. The potential of miRNAs for diagnosis, treatment and monitoring of breast cancer. Scand J Clin Lab Invest Suppl. 2016;245:S34–9.PubMedCrossRef
12.
Zurück zum Zitat Zhao F, Lv J, Gan H, Li Y, Wang R, Zhang H, et al. MiRNA profile of osteosarcoma with CD117 and stro-1 expression: miR-1247 functions as an onco-miRNA by targeting MAP3K9. Int J Clin Exp Pathol. 2015;8(2):1451–8.PubMedPubMedCentral Zhao F, Lv J, Gan H, Li Y, Wang R, Zhang H, et al. MiRNA profile of osteosarcoma with CD117 and stro-1 expression: miR-1247 functions as an onco-miRNA by targeting MAP3K9. Int J Clin Exp Pathol. 2015;8(2):1451–8.PubMedPubMedCentral
13.
Zurück zum Zitat Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–22.PubMedCrossRef Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–22.PubMedCrossRef
14.
Zurück zum Zitat Mocellin S, Pasquali S, Pilati P. Oncomirs: from tumor biology to molecularly targeted anticancer strategies. Mini Rev Med Chem. 2009;9(1):70–80.PubMedCrossRef Mocellin S, Pasquali S, Pilati P. Oncomirs: from tumor biology to molecularly targeted anticancer strategies. Mini Rev Med Chem. 2009;9(1):70–80.PubMedCrossRef
17.
Zurück zum Zitat Gonzalez Dos Anjos L, de Almeida BC, Gomes de Almeida T, Mourao Lavorato Rocha A, De Nardo Maffazioli G, Soares FA, et al. Could miRNA signatures be useful for predicting uterine sarcoma and carcinosarcoma prognosis and treatment. Cancers (Basel). 2018;10(9):315. https://doi.org/10.3390/cancers10090315.CrossRef Gonzalez Dos Anjos L, de Almeida BC, Gomes de Almeida T, Mourao Lavorato Rocha A, De Nardo Maffazioli G, Soares FA, et al. Could miRNA signatures be useful for predicting uterine sarcoma and carcinosarcoma prognosis and treatment. Cancers (Basel). 2018;10(9):315. https://​doi.​org/​10.​3390/​cancers10090315.CrossRef
18.
Zurück zum Zitat Pazzaglia L, Novello C, Conti A, Pollino S, Picci P, Benassi MS. miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma. Cell Oncol (Dordr). 2017;40(1):77–88.CrossRef Pazzaglia L, Novello C, Conti A, Pollino S, Picci P, Benassi MS. miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma. Cell Oncol (Dordr). 2017;40(1):77–88.CrossRef
19.
Zurück zum Zitat Benna C, Rajendran S, Spiro G, Tropea S, Del Fiore P, Rossi CR, et al. Associations of clock genes polymorphisms with soft tissue sarcoma susceptibility and prognosis. J Transl Med. 2018;16(1):338.PubMedPubMedCentralCrossRef Benna C, Rajendran S, Spiro G, Tropea S, Del Fiore P, Rossi CR, et al. Associations of clock genes polymorphisms with soft tissue sarcoma susceptibility and prognosis. J Transl Med. 2018;16(1):338.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Sarver AL, Phalak R, Thayanithy V, Subramanian S. S-MED: sarcoma microRNA expression database. Lab Invest. 2010;90(5):753.PubMedCrossRef Sarver AL, Phalak R, Thayanithy V, Subramanian S. S-MED: sarcoma microRNA expression database. Lab Invest. 2010;90(5):753.PubMedCrossRef
22.
Zurück zum Zitat Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90–7.PubMedPubMedCentralCrossRef Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90–7.PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.CrossRef Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.CrossRef
25.
Zurück zum Zitat Rivals I, Personnaz L, Taing L, Potier MC. Enrichment or depletion of a GO category within a class of genes: which test? Bioinformatics. 2007;23(4):401–7.PubMedCrossRef Rivals I, Personnaz L, Taing L, Potier MC. Enrichment or depletion of a GO category within a class of genes: which test? Bioinformatics. 2007;23(4):401–7.PubMedCrossRef
26.
Zurück zum Zitat Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA. 2003;100(16):9440–5.PubMedCrossRef Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA. 2003;100(16):9440–5.PubMedCrossRef
27.
Zurück zum Zitat Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362–8.PubMedCrossRef Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362–8.PubMedCrossRef
28.
Zurück zum Zitat White RJ. RNA polymerases I and III, non-coding RNAs and cancer. Trends Genet. 2008;24(12):622–9.PubMedCrossRef White RJ. RNA polymerases I and III, non-coding RNAs and cancer. Trends Genet. 2008;24(12):622–9.PubMedCrossRef
29.
30.
Zurück zum Zitat Winter AG, Sourvinos G, Allison SJ, Tosh K, Scott PH, Spandidos DA, et al. RNA polymerase III transcription factor TFIIIC2 is overexpressed in ovarian tumors. Proc Natl Acad Sci USA. 2000;97(23):12619–24.PubMedCrossRef Winter AG, Sourvinos G, Allison SJ, Tosh K, Scott PH, Spandidos DA, et al. RNA polymerase III transcription factor TFIIIC2 is overexpressed in ovarian tumors. Proc Natl Acad Sci USA. 2000;97(23):12619–24.PubMedCrossRef
31.
Zurück zum Zitat Chen W, Heierhorst J, Brosius J, Tiedge H. Expression of neural BC1 RNA: induction in murine tumours. Eur J Cancer. 1997;33(2):288–92.PubMedCrossRef Chen W, Heierhorst J, Brosius J, Tiedge H. Expression of neural BC1 RNA: induction in murine tumours. Eur J Cancer. 1997;33(2):288–92.PubMedCrossRef
32.
Zurück zum Zitat Chen W, Bocker W, Brosius J, Tiedge H. Expression of neural BC200 RNA in human tumours. J Pathol. 1997;183(3):345–51.PubMedCrossRef Chen W, Bocker W, Brosius J, Tiedge H. Expression of neural BC200 RNA in human tumours. J Pathol. 1997;183(3):345–51.PubMedCrossRef
33.
Zurück zum Zitat White RJ, Trouche D, Martin K, Jackson SP, Kouzarides T. Repression of RNA polymerase III transcription by the retinoblastoma protein. Nature. 1996;382(6586):88–90.PubMedCrossRef White RJ, Trouche D, Martin K, Jackson SP, Kouzarides T. Repression of RNA polymerase III transcription by the retinoblastoma protein. Nature. 1996;382(6586):88–90.PubMedCrossRef
34.
Zurück zum Zitat Crighton D, Woiwode A, Zhang C, Mandavia N, Morton JP, Warnock LJ, et al. p53 represses RNA polymerase III transcription by targeting TBP and inhibiting promoter occupancy by TFIIIB. EMBO J. 2003;22(11):2810–20.PubMedPubMedCentralCrossRef Crighton D, Woiwode A, Zhang C, Mandavia N, Morton JP, Warnock LJ, et al. p53 represses RNA polymerase III transcription by targeting TBP and inhibiting promoter occupancy by TFIIIB. EMBO J. 2003;22(11):2810–20.PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Rapino F, Delaunay S, Zhou Z, Chariot A, Close P. tRNA modification: is cancer having a wobble? Trends Cancer. 2017;3(4):249–52.PubMedCrossRef Rapino F, Delaunay S, Zhou Z, Chariot A, Close P. tRNA modification: is cancer having a wobble? Trends Cancer. 2017;3(4):249–52.PubMedCrossRef
36.
Zurück zum Zitat Arias-Carrion O, Stamelou M, Murillo-Rodriguez E, Menendez-Gonzalez M, Poppel E. Dopaminergic reward system: a short integrative review. Int Arch Med. 2010;3:24.PubMedPubMedCentralCrossRef Arias-Carrion O, Stamelou M, Murillo-Rodriguez E, Menendez-Gonzalez M, Poppel E. Dopaminergic reward system: a short integrative review. Int Arch Med. 2010;3:24.PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Ayano G. Dopamine: receptors, functions, synthesis, pathways, locations and mental disorders: review of literatures. J Mental Disord Treat. 2016;2(2):2–5.CrossRef Ayano G. Dopamine: receptors, functions, synthesis, pathways, locations and mental disorders: review of literatures. J Mental Disord Treat. 2016;2(2):2–5.CrossRef
38.
Zurück zum Zitat Mizuta K, Zhang Y, Xu D, Mizuta F, D’Ovidio F, Masaki E, et al. The dopamine D1 receptor is expressed and facilitates relaxation in airway smooth muscle. Respir Res. 2013;14:89.PubMedPubMedCentralCrossRef Mizuta K, Zhang Y, Xu D, Mizuta F, D’Ovidio F, Masaki E, et al. The dopamine D1 receptor is expressed and facilitates relaxation in airway smooth muscle. Respir Res. 2013;14:89.PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Zeng C, Han Y, Huang H, Yu C, Ren H, Shi W, et al. D1-like receptors inhibit insulin-induced vascular smooth muscle cell proliferation via down-regulation of insulin receptor expression. J Hypertens. 2009;27(5):1033–41.PubMedPubMedCentralCrossRef Zeng C, Han Y, Huang H, Yu C, Ren H, Shi W, et al. D1-like receptors inhibit insulin-induced vascular smooth muscle cell proliferation via down-regulation of insulin receptor expression. J Hypertens. 2009;27(5):1033–41.PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Gao J, Zhang C, Gao F, Li H. The effect and mechanism of dopamine D1 receptors on the proliferation of osteosarcoma cells. Mol Cell Biochem. 2017;430(1–2):31–6.PubMedCrossRef Gao J, Zhang C, Gao F, Li H. The effect and mechanism of dopamine D1 receptors on the proliferation of osteosarcoma cells. Mol Cell Biochem. 2017;430(1–2):31–6.PubMedCrossRef
41.
Zurück zum Zitat Gao J, Gao F. Dopamine D1 receptors induce apoptosis of osteosarcoma cells via changes of MAPK pathway. Clin Exp Pharmacol Physiol. 2017;44(11):1166–8.PubMedCrossRef Gao J, Gao F. Dopamine D1 receptors induce apoptosis of osteosarcoma cells via changes of MAPK pathway. Clin Exp Pharmacol Physiol. 2017;44(11):1166–8.PubMedCrossRef
43.
44.
Zurück zum Zitat Wu J, Zhong D, Wu X, Sha M, Kang L, Ding Z. Voltage-gated potassium channel Kv1.3 is highly expressed in human osteosarcoma and promotes osteosarcoma growth. Int J Mol Sci. 2013;14(9):19245–56.PubMedPubMedCentralCrossRef Wu J, Zhong D, Wu X, Sha M, Kang L, Ding Z. Voltage-gated potassium channel Kv1.3 is highly expressed in human osteosarcoma and promotes osteosarcoma growth. Int J Mol Sci. 2013;14(9):19245–56.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Wu J, Zhong D, Fu X, Liu Q, Kang L, Ding Z. Silencing of Ether à go-go 1 by shRNA inhibits osteosarcoma growth and cell cycle progression. Int J Mol Sci. 2014;15(4):5570–81.PubMedPubMedCentralCrossRef Wu J, Zhong D, Fu X, Liu Q, Kang L, Ding Z. Silencing of Ether à go-go 1 by shRNA inhibits osteosarcoma growth and cell cycle progression. Int J Mol Sci. 2014;15(4):5570–81.PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Wu J, Chen Z, Liu Q, Zeng W, Wu X, Lin B. Silencing of Kv1.5 gene inhibits proliferation and induces apoptosis of osteosarcoma cells. Int J Mol Sci. 2015;16(11):26914–26.PubMedPubMedCentralCrossRef Wu J, Chen Z, Liu Q, Zeng W, Wu X, Lin B. Silencing of Kv1.5 gene inhibits proliferation and induces apoptosis of osteosarcoma cells. Int J Mol Sci. 2015;16(11):26914–26.PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Burroughs AM, Ando Y, de Hoon MJ, Tomaru Y, Suzuki H, Hayashizaki Y, et al. Deep-sequencing of human Argonaute-associated small RNAs provides insight into miRNA sorting and reveals Argonaute association with RNA fragments of diverse origin. RNA Biol. 2011;8(1):158–77.PubMedPubMedCentralCrossRef Burroughs AM, Ando Y, de Hoon MJ, Tomaru Y, Suzuki H, Hayashizaki Y, et al. Deep-sequencing of human Argonaute-associated small RNAs provides insight into miRNA sorting and reveals Argonaute association with RNA fragments of diverse origin. RNA Biol. 2011;8(1):158–77.PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Jazdzewski K, Liyanarachchi S, Swierniak M, Pachucki J, Ringel MD, Jarzab B, et al. Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci USA. 2009;106(5):1502–5.PubMedCrossRef Jazdzewski K, Liyanarachchi S, Swierniak M, Pachucki J, Ringel MD, Jarzab B, et al. Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci USA. 2009;106(5):1502–5.PubMedCrossRef
Metadaten
Titel
miRNA deregulation targets specific pathways in leiomyosarcoma development: an in silico analysis
verfasst von
Clara Benna
Senthilkumar Rajendran
Marco Rastrelli
Simone Mocellin
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
Journal of Translational Medicine / Ausgabe 1/2019
Elektronische ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-019-1907-2

Weitere Artikel der Ausgabe 1/2019

Journal of Translational Medicine 1/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.